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Abstract 
Homologous or receptor-specific desensitization ofj%adrenergic receptors is thought to be triggered by receptor phosphorylation mediated by the 
h-adrenergic receptor kinases (BARK). Upon receptor activation, cytosolic~ARK translocates to the membrane, probably by binding to G-protein 
By-subunits. Using the puritied proteins reconstituted into phospholipid vesicles we show here that this binding process can be inhibited by phosducin, 
a cytosolic protein that has recently been described as a regulator of G-protein-m~iated signalling. Phosducin appears to complete very effectively 
with /3ARK for the G-protein &-subunits. These inhibitory effects of phosducin on receptor phosphorylation are antagonized following phospho- 
rylation of phosducin by protein kinase A. It is proposed that phosducin may act as a regulator of homologous/I-adrenergic receptor desensitization. 
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Signal transduction via G-protein-coupled receptors is 
regulated by multiple mechanisms, which have been in- 
vestigated most thoroughly for the ~-adrenergic recep- 
tor/G,/adenylyl cyclase [I] and the rhodopsin/G&y- 
clicGMP phosphodiesterase [Z] systems. Many of these 
mechanisms reduce receptor function in response to pro- 
longed or repeated receptor stimulation, a phenomenon 
that is termed desensitization [3,4]. A major mechanism 
causing /I-adrenergic receptor desensitization involves 
receptor phosphorylation catalyzed by the /I-adrenergic 
receptor kinase (@ARK), followed by binding of /I-ar- 
restin to the phosphory~ated receptors [5-81. This mech- 
anism, which can be mediated by two similar isoforms 
of both BARK 193 and /3-arrestin [lo], appears to be the 
most rapid (tm < 15 s) and quantitatively most impor- 
tant (> N--70% loss of receptor function) mechanism 
causing desensitization of these and possibly other re- 
lated receptors [ 11,121. BARK-catalyzed phosphoryla- 
tion is specific for activated receptors because only the 
agonist-occupied receptors are a good substrate for 
j3ARK [5]. More recently, a second agonist-dependent 
process enhancing HARK-mediated phosphorylation 
has been identified: generation of activated G-proteins 
[13,14], so that their dissociated~~-subunits can serve as 
a membrane anchor for the cytosolic BARK [15]. The 
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extent of this anchoring function of &-subunits for 
BARK has been shown to vary amoung different sub- 
types of @- and y-subunits [16]. 
Protein kinase A can also phosphorylate /3-adrenergic 
receptors [171, and this phosphorylation appears to cause 
per se desensitization, i.e. a reduction of the receptors’ 
ability to activate G, [11,17-211. Most data suggest hat 
thepARK-mediated and the PKA-mediated pathways of 
~-adrener~c receptor desensitization are inde~ndent 
events [I 1 ,I 8,191. However, in the case of olfactory re- 
ceptor desensitization both PKA- and @ARK-like ki- 
nases appear to be required to effect desensitization [223. 
One possible explanation for these data is that BARK. 
may be under the tonic control of an as yet unknown 
inhibitor, and that PKA may be capable of relieving this 
inhibition. 
We have recently described that phosducin, a protein 
that had been thought to be specific for the retina and 
the developmentally related pineal gland [23,24], is a 
ubiquitous G-protein regulator [ZS]. Phosducin can bind 
to several different G-proteins, such as G,, G,, and Gi, 
and inhibits theit GTPase- as well as their si~alling 
functions [25]. Therefore, in the present study, we exam- 
ined whether phosducin might also interfere with the 
enhancing effects of G-proteins on BARK-mediated re- 
ceptor phosphorylation using purified components re- 
constituted in phospholipid vesicles. Furthermore, since 
we had shown earlier that inhibition of G-protein func- 
tion by phosducin was abolished following its phospho- 
rylation by PKA [25], we investigated the effects of PKA- 
mediated phosphorylation of phosducin on /3ARK 
translocation. 
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2. Materials and methods 
2.1. Protein purification and reconstitution 
Human &adrenergic receptors were expressed in Sf9 cells, and were 
purified by affinity chromatography [26]. BovineBARK- (which is the 
major isoform of BARK for the phosphorylation of &adrenergic re- 
ceptors; [9]) was expressed using the same system and purified [27]. 
Recombinant phosducin was purified from E. coli [25]. Purified & 
receptors and G, purified from rabbit liver [28] were reconstituted into 
phosphatidylcholine vesicles [29]. Urea-treated rod outer segments con- 
taining > 95% rhodopsin were prepared from bovine retina [30]. 
2.2. Receptor phosphorylation 
20,ul of vesicles containing 1 pmol of receptors and various amounts 
of G, or resolved bovine brain G-protein By-subunits were 
phosphorylated with 0.5 pmol purified BARK (= 4 nM) in an assay 
volume of 120 ~1 containing 20 mM Tris-HCl, pH 7.4,2 mM EDTA, 
8 mM MgCl,, 1 mM dithiothreitol, 50 ,uM [Y-~‘P]ATP (1 @i/tube) 
during a 30 min incubation at 30°C (-)Isoproterenol and GTP were 
present at 10 PM to activate receptors and G,. Purified phosducin was 
present during this phosphorylation reaction in various concentrations. 
In some assays, phosducin was phosphorylated with purified PKA [31] 
prior to the BARK assays; for those assays, control phosducin was 
incubated under the same conditions but without PKA. Following 
phosphorylation by PKA, 5 PM protein kinase inhibitor (PKI, Sigma) 
was also included in order to prevent further phosphoryl&ion of puri: 
fied proteins. PKI did not inhibit suecific receutor ohosuhorvlation bv 
/3AR‘K (not shown). The receptor phospho$ation <y BARK w& 
stopped with 1 ml of ice-cold incubation buffer and centrifugation at 
300,000 x g for 30 min, and the pellets were subjected to SDS-PAGE. 
The phosphorylated bands were visualized by autoradiography, and the 
radioactivity incorporated into the receptor band was quantitated by 
Cerenkov counting. 
Rod outer segments (= 25 pmol rhodopsin/60 ~1) were phos- 
phorylated in a similar manner, except hat bright white light was used 
for activation, and the incubation time was 10 min. Assay conditions 
for phosphorylation of the soluble BARK-substrate peptide 
RRRAAEAASAAA (2 mM, [32]) by purified recombinant /3ARK 
(15 nM) were similar to those used for receptor vesicles, except hat the 
assay volume was 30 ~1 and BSA was added to 0.5 mg/ml. The incuba- 
tions were stopped by spotting onto Whatman P-81 phosphocellulose 
paper and immersion in phosphoric acid [32]. 
2.3. Data analysis 
Concentration-response curves were analyzed by non-linear curve- 
fitting in order to determine ICso values as described [33]. Unless stated 
otherwise all data are from at least 3 independent experiments. 
3. Results 
In a system consisting of the purified components, 
/?,-adrenergic receptors and G, reconstituted into phos- 
pholipid vesicles, addition of phosducin markedly inhib- 
ited BARK-catalyzed receptor phosphorylation (Fig. 
1A). The presence of G, increased phosphorylation more 
than lo-fold to 2 mol phosphate/mol receptor. Similar 
results were obtained with resolved G-protein By-sub- 
units instead of G, (not shown). Phosducin completely 
negated this enhancing effect of G,, with half-maximal 
inhibition achieved at a ratio of phosducin:G, of below 
2. Considering that phosducin is a soluble protein 
whereas G, was reconstituted into the vesicles, this shows 
a remarkable potency of phosducin and suggests that 
inhibition may be caused by formation of a 1:l 
phosducin-G-protein complex. Similar effects were ob- 
served when the extent of phosphorylation was increased 
(6 mol phosphate/m01 receptor), either by extended incu- 
bation times or by the use of higher PARK concentra- 
tions (not shown). G-proteins were required for the inhi- 
bition, since phosducin had no effect on the residual 
phosphorylation occurring in the absence of G-proteins 
(not shown). 
BARK can also phosphorylate rhodopsin in a light- 
dependent manner, albeit to a much lower degree than 
the specific rhodopsin kinase [34]. Phosducin was an 
equally potent inhibitor in this system (Fig. 1B). In these 
experiments, we added G-protein &-subunits to rod 
outer segments, which contain > 95% rhodopsin. The 
resolved &-subunits caused an > 5-fold enhancement in 
phosphorylation (Fig. lB), and similar results were ob- 
tained with trimeric G, (not shown). Again, this enhance- 
ment was completely reversed by phosducin. Half-maxi- 
mal inhibition occurred at = 155 nM phosducin; this 
value is = 5 times higher than the one that can be esti- 
mated from Fig. 1A (< 33 nM), in line with the 6-fold 
higher By-subunit concentration which was used in these 
experiments, and corresponds to a molar ratio 
(phosducin$y-subunit) of 1.5. When a short sol- 
uble peptide substrate [32] for /3ARK was used (Fig. 1 C), 
there was no inhibition even by high concentrations of 
phosducin (600 nM, 40-fold molar excess over BARK), 
suggesting that phosducin does not directly inhibit 
BARK. 
Phosducin inhibited the association of BARK with the 
phospholipid vesicles in the presence of G-protein j?r- 
subunits (Fig. 2A) or trimeric G, (not shown). The de- 
crease of vesicle-associated BARK as demonstrated by 
Coomassie blue staining of the vesicle components was 
paralleled by decreased vesicular BARK-activity as 
measured by BARK-autophosphorylation (Fig. 2A) or 
&receptor phosphorylation (not shown). In the absence 
of G-proteins or their &-subunits there were no detecta- 
ble amounts of /3ARK associated with the vesicles as 
shown by Coomassie blue staining. This extent was not 
altered by the presence of phosducin (not shown). Thus, 
phosducin could displace BARK from jly-subunit-con- 
taining vesicles. In a reciprocal manner, @ARK could 
displace phosducin from the same vesicles (Fig. 2B), but 
a higher stoichiometry of BARK vs. phosducin was re- 
quired. This suggests that BARK and phosducin com- 
pete for G-protein-py-subunits as membrane anchors, 
with phosducin being the more potent competitor. 
We have shown earlier [25] that the inhibitor effects of 
phosducin on G-protein-mediated signalling were almost 
completely lost after phosphorylation of phosducin by 
protein kinase A (PKA), which occurs as serine-73 [35]. 
Similarly, the inhibitory effects of phosducin on G-pro- 
tein-enhanced &-receptor phosphorylation were mark- 
edly impaired by PKA-mediated phosphorylation of 
phosducin (Fig. 3). PKA-phosphorylated phosducin was 
more than IO-fold less potent than non-phosphorylated 
(but similarly treated) phosducin. 
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The I&, value for control phosducin in this experi- 
ment (= 80 nM) was higher than the one that can be 
estimated from Fig. 1A (C 33 nM). This may be due to 
the higher /IARK concentration used in the experiment 
shown in Fig. 3. Dependence of the I&, value both on 
the amounts of G-protein By-subunits (Fig. 1A vs. Fig. 
1B) and the concentration of BARK (Fig. 1A vs. Fig. 3) 
is consistent with the notion of competition of BARK 
and phosducin for the /?y-subunits as membrane an- 
chors. 
L 
0 control 
l + phosducin (600nM) 
0 20 40 60 80 100 
time (min) 
Fig. 1. Effects of phosducin on BARK-catalyzed phosphorylation. (A) 
Inhibition of the phosphorylation of purified /I,-adrenergic receptors 
reconstituted with or without purified G, into phospholipid vesicles. 
Top panel: autoradiogram of phosphorylated receptors after electro- 
phoresis on an SDS-polyacrylamide gel. Bottom panel: quantitation of 
phosphate incorporation into receptors. 20 ~1 of vesicles containing 1 
pmol of receptors and 0 or 2 pmol of G, (as indicated) were phos- 
phorylated with 0.5 pmol purified BARK (= 4 nM) in the presence of 
0, 4 or 20 pmol purified phosducin (= 33 and = 167 nM) in an assay 
volume of 120 ~1. (B) Inhibition of the phosphorylation of rhodopsin 
in rod outer segments in the presence of G-protein&-subunits purified 
from bovine brain. Top panel: autoradiogram of phosphorylated rho- 
dopsin after electrophoresis on an SDS-polyacrylamide gel. Bottom 
panel: quantitation of phosphate incorporation into rhodopsin. Urea- 
treated rod outer segments (= 25 pmol rhodopsin) were phos- 
phorylated in the presence of resolved bovine brain G-protein By-sub- 
units (0 or 6 pmol) in an assay volume of 60 pl-assay. Curve-fitting [33] 
gave an IC,, value of 9.3 pmol phosducin (= 155 nM). (C) Unaltered 
phosphorylation of a peptide substrate by BARK in the presence of 
phosducin. The synthetic peptide RRRAAEAASAAA (2 mM) was 
phosphotylated by purified recombinant BARK (15 nM) in the absence 
(0) or presence (0) of purified recombinant phosducin (600 nM), and 
phosphate incorporation was determined after the indicated incubation 
times. Data in all panels are from single experiments representative of
at least three similar experiments. 
4. Discussion 
The recent discovery of a role for G-proteins in the 
phosphorylation and, hence, presumably the desensitiza- 
tion of /3-adrenergic as well as muscarinic receptors has 
added a new level of complexity to the mechanisms reg- 
ulating these receptors. We now find that this regulatory 
role of G-proteins may itself be subject to regulation by 
phosducin. In its non-phosphorylated state phosducin 
can bind to G-proteins; this binding appears to occur 
primarily to the By-subunits of G-proteins [23,25]. When 
phosducin is bound to G-proteins, it inhibits binding of 
BARK to the G-protein By-subunits and thereby reduces 
BARK-mediated receptor phosphorylation. Following 
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phosphorylation of phosducin by PKA phosducin ap- 
pears to dissociate from the G-proteins and to permit 
binding of /IARK to the /3y-subunits of the activated 
G-proteins, and thus allow receptor desensitization. In 
agreement with earlier data, the interaction of phosducin 
with G-protein &-subunits seems to depend on the 
phosphorylation status of phosducin. 
These hypotheses uggest hat /I-adrenergic receptors, 
as well as possibly other related receptors, are embedded 
in a complex network regulating their function, and that 
phosducin may be a component of this network. It may 
have dual functions in this receptor system: in its non- 
phosphorylated state it may dampen G-protein-medi- 
ated signalling [25] but may at the same time reduce 
BARK-mediated receptor desensitization. In its phos- 
phorylated state, it might dissociate from the G-proteins 
and thereby permit receptor desensitization. Further ex- 
periments will have to address the question whether in- 
tracellular phosducin levels are sufficient to exert a sim- 
ilar inhibition of receptor phosphorylation under physio- 
logical conditions. 
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Fig. 2. Competition ofpARK and phosducin for G-protein/3y-subunits 
in phospholipid vesicles. (A) Phosducin inhibits the association of 
BARK with /?y-containing vesicles. (B) BARK inhibits the association 
of phosducin with By-containing vesicles. Shown are vesicle-associated 
/IARK (A, top panel: autophosphorylation of @ARK, bottom panel: 
Coomassie-stain of BARK) or phosducin (B, Coomassie stain) after 
incubation of &receptor (1 pmol)- and G-protein &-subunit 
(8 pmol)-containing phospholipid vesicles with a constant amount of 
BARK and varying amounts of phosducin at ratios phosducin$ARK 
of 0, 8 and 40 (A) or a constant amount of phosducin and varying 
amounts ofbARK givingj?ARK:phosducin ratios of 0,840. (B). The 
assay contained 50 PM [Y-~*P]ATP to allow visualization of BARK by 
autophosphorylation, and were carried out as described under meth- 
ods. Vesicle-associated proteins were identified by SDS-PAGE of the 
vesicle pellet and subsequent autoradiography or Coomassie-staining 
of the gels. 
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Fig. 3. PKA-catalyzed phosphorylation of phosducin antagonizes its 
inhibitory effects on G-protein-dependent&adrenergic receptor phos- 
phorylation. Top panel: autoradiogram of phosphorylated receptors 
after electrophoresis on an SDS-polyacrylamide gel. Bottom panel: 
quantitation of phosphate incorporation into receptors. &adrenergic 
receptors (0.5 pmol/tube) were reconstituted with or without G, 
(3 pmohtube) and phosphorylated by BARK (5 pmohtube) in the ab- 
sence or presence of varying concentrations of phosducin. Phosducin 
was phosphorylated by PKA (or treated similarly without PKA: con- 
trol phosducin) prior to the assay. Further PKA-mediated phosphoryl- 
ation was then blocked by the addition of 5 PM PKl. Phosducin was 
present at 0, 6, 20, 60 or 200 pmol/tube, giving molar phosducin/G, 
ratios of 0, 2, 6, 20 and 60. IC,, values calculated by curve-fitting [33] 
were = 80 nM (control phosducin) and = 1000 nM (PKA-phos- 
phorylated phosducin). 
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